Navigation Links
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Date:5/20/2009

mm) and/or chronic total occlusions. Two year follow up was obtained in all patients, with the exception of one.

The next generation of pro-healing stent technologies was highlighted in separate presentations, one focusing on pre-clinical results of an endothelial cell capture (EPC) surface on an abluminal, low dose sirolimus eluting stent (pro-healing SES), the other focusing on the company's bioabsorbable stent developments.

Greg Kaluza, M.D., Ph.D., Director of Operations at the Jack H. Skirball Center for Cardiovascular Research in New York, presented the pro-healing SES's pre-clinical results from multiple models supporting the soon to be initiated first in human study. The pro-healing SES demonstrated significantly lower neointimal hyperplasia, while also showing improved endothelial coverage relative to two other commercially available DES. There was also a noticeably lower presence of inflammation and foreign body reaction. "These data are remarkably promising across all criterion," said Kaluza. "For the first time, a DES appears effective at inhibition of neointima while enhancing endothelial coverage early on."

Development of the company's bioabsorbable stent program was presented by Robert Cottone, vice president of intellectual property and technologies. Angiographic and optical coherence tomography (OCT) imagery were reviewed illustrating the new stent platform's deliverability, design features, and vessel scaffolding. "The nature of the polymeric materials allows for tremendous innovation in stent design and functionality," said Cottone. "With this new platform, combined with our coating technologies, we will be able to achieve clinical vascular restoration therapies simply not possible with metal."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream an
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
2. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
3. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
4. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
5. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
6. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... investigating the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... only $158.00 per share. Concerned SLXP investors are encouraged ... . The investigation focuses upon the ... proposed agreement, Salix shareholders would receive only $158.00 per ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015  Boston Scientific ... participate in the Barclays 2015 Annual Healthcare Conference on ... Dan Brennan , executive vice president ... vice president, Investor Relations, will participate in a 25-minute ... host analyst at approximately 1:05 p.m. ET. Following a ...
(Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... PHILADELPHIA, Pa. June 20 GlaxoSmithKline,(NYSE: GSK ... and Drug,Administration has extended the priority review period ... treated patients,with chronic idiopathic thrombocytopenic purpura, as they ... Drug User Fee action date has,been extended to ...
... OAK LAWN, Ill., June 20 Advocate Christ,Medical Center ... a few institutions,in the Chicago area, the only one ... hospitals nationally that are using a glue-like liquid for,the ... a recent two-and-a-half-hour procedure, Thomas J. Grobelny MD, of,the ...
Cached Medicine Technology:GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2
(Date:3/2/2015)... Final Cut Pro X plugin ... from Pixel Film Studios. , “The TranStatic Volume 2 plugin ... Christina Austin, CEO of Pixel Film Studios. “TranStatic Volume 2 ... Pro X editors toolbox.” , With TranStatic Volume 2 users ... altering static scrambling effects from Pixel Film Studios. Users have ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 ... services and manage their practices compliantly and ... integrated all-inclusive solution. The interoperability between ... and a medical practice management system is ... long-term financial sustainability. A referral management and ...
(Date:3/1/2015)... (PRWEB) March 02, 2015 As ... web works co-founders, Michael Burns and Carita Weaver, ... addition to working with the Southlake Chamber of ... i5 web works recently launched a website for ... , A primary communications tool for Hill’s campaign, ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Adults who ... insurance rates for term or universal policies can now ... of the best life insurance companies for single adults ... system at http://quotespros.com/life-insurance.html . , The rate plans ... portal are tied to a number of life protection ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2
... Experience with Complex Rehab Market , , ... rehab specialist with 35 years of experience, has joined ... fastest growing complex rehab companies. O,Neill is an Assistive ... www.alliance-seating.com ) and is responsible for sales and service of ...
... muscular atrophy, a neurodegenerative disorder that causes the weakening ... and occurs in 1 in 6,000 live births. ... impressive results as a treatment for spinal muscular atrophy ... to translate the therapy to the human body. A ...
... Mo. Evolving HIV viral strains and the adverse ... treatments propel scientists to continue exploring alternative HIV ... Missouri researcher has identified broad-spectrum aptamers. Aptamers are ... reproducing. In lab tests, aptamers known as RT5, ...
... TriCipher will host an,informative Webinar detailing ... pharmaceutical and health care industries and strategies,for securing ... one hour webinar on December 16th brings together ... discuss how digital signatures have,benefited and streamlined research ...
... of voriconazole in combating fungal infections has been confirmed ... International Journal of Antimicrobial Agents ( www.elsevier.com/locate/ijaa ... with weakened immune systems, which can be caused by ... reinforces earlier findings that this drug is a potent ...
... Dec. 16 WellPoint, Inc. (NYSE: WLP ... today,announced plans to collaboratively partner with four Blue Cross ... to online, consumer-friendly,health care cost information. , ... WellPoint in this initiative are,Highmark Inc. (Pennsylvania), Premera Blue ...
Cached Medicine News:Health News:Veteran Rehab Specialist, Ted O'Neill, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Researcher refining synthetic molecules to prevent HIV resistance 2Health News:Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures 2Health News:Pharmaceutical and Health Care Experts to Detail Cost-Cutting Capabilities of Secure Digital Signatures 3Health News:Voriconazole: A highly potent treatment for fungal infections 2Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 2Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 3Health News:WellPoint Announces Collaborative Partnership to Expand Access to Health Care Provider Information 4
For the detection of pan specific pLDH, utilizing whole blood samples. Parabank excludes infected blood from the blood supply in the blood bags....
192 Test Enzyme Immunoassay for the detection of Human IgG antibodies to all four forms of Malaria....
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (2 line, PAN specific-pLDH)...
Medicine Products: